PSMA-BCH

P014
Grade:
GMP product
Tested for sterility and bacterial endotoxins
Description:
PSMA-BCH, also known as NOTA-PSMA, is a PSMA-NOTA-conjugated precursor.
⁶⁸Ga-PSMA-BCH can be used for prostate cancer imaging.
Al¹⁸F-PSMA-BCH is a novel ¹⁸F PET radiotracer for prostate cancer.
⁶⁴Cu-PSMA-BCH is a new radiotracer for delayed PET imaging of prostate cancer. It is PSMA-specific, shows high in vivo stability, and has lower liver uptake compared to ⁶⁴Cu-PSMA-617.
Biodistribution studies in mice and PCa patients revealed a similar profile to other PSMA ligands. The compound was found to be safe and exhibited moderate effective dosimetry.
Synonyms:
NOTA-PSMA
Molar weight:
941.03 g/mol (net substance)
Molecular formula:
C₄₅H₆₄N₈O₁₄ (net substance)
CAS №:
1703768-74-4
Retest date:
Not less than 18 months from the manufacturing date
Packaging:
2R/4ml or 8R/10ml Type I glass vials with bromobutyl rubber stoppers
Storage conditions:
–20 ±5 °C
Transportation at 2–8 °C (less than 1 month)
Available quantities:
0.1 mg; 1.0 mg; custom quantity upon request
Quality parameters

Quality parameters

Appearance: White solid
Identification:
– HPLC: Retention time of main peak corresponds to the PSMA-BCH reference standard
– Mass spectrometry: m/z = 941.0 ± 4
Residual heavy metals (ICP-OES): ≤ 100 ppm
Purity (HPLC): ≥ 98.0%
Bacterial endotoxins (gel-clot method): ≤ 10.0 EU/vial
Sterility (direct inoculation method): Sterile (passes test)
Sterility tests are performed for sterile products, made in aseptic conditions (class A).
Other products